Pharmacokinetics of emtricitabine/tenofovir disoproxil fumarate among transgender adolescents and young adults without HIV receiving gender affirming hormones.
Sign Up to like & getrecommendations! Published in 2022 at "AIDS research and human retroviruses"
DOI: 10.1089/aid.2022.0043
Abstract: The transgender community has expressed concerns regarding drug-drug interactions between HIV-pre-exposure prophylaxis (PrEP) and gender-affirming hormones. In this study, we evaluated emtricitabine (F, FTC)/tenofovir disoporoxil fumarate (TDF) pharmacokinetics among adolescent and young adult transgender persons… read more here.
Keywords: transgender; receiving gender; gender affirming; ftc ... See more keywords